Role of Finerenone in the management of diabetic kidney disease: A comprehensive review

A significant microvascular consequence of type 2 diabetes mellitus (T2DM), diabetic kidney disease (DKD) is a major global cause of end-stage renal disease (ESRD) and chronic kidney disease (CKD) [1, 2]. The two main characteristics of DKD are progressive glomerular filtration rate (GFR) decline and persistent albuminuria. There is still a significant residual danger to the kidneys and heart even with the introduction of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and improved renin-angiotensin-aldosterone system inhibition (RAAS) [3]. In patients with DKD, finerenone, a new non-steroidal mineralocorticoid receptor antagonist (MRA), has shown promise as a treatment alternative to slow the course of renal disease and cardiovascular events [4-6]. The pathophysiologic justification, clinical data, safety, efficacy, guidelines, and future prospects of finerenone in the treatment of DKD are all summarized in this review.